Genome-wide CRISPR/Cas9 screening identified genes that contributed to panobinostat resistance. (A) Schematic outline of the genome wide CRISPR/Cas9 loss-of-function screening. (B) Enriched genes by P value rank after CRISPR/Cas9 screening at day 14 after panobinostat treatment. (C-H) Validation of selected genes in the CRISPR/Cas9 screening using an MTT assay in Nalm6-Cas9 cells. Nalm6-Cas9 cells were infected with empty vector (CON) or sgRNA vectors to disturb targeted gene expression. Each experiment was in triplicate and repeated 3 times. Data represent mean ± standard deviation (SD; n = 3).